

Aug, 2018

1. PERSONAL INFORMATION

Mahmoud Suleiman

ID Number: 024789760

Date of birth: January 14, 1970

Place of birth: Nazareth, Israel

Citizenship: Israel

Marital Status: Married +3

Address:

Home: Moran 44/2, Nazareth Illit, Israel.

Work: Cardiology, Rambam Health Care Campus, Haifa 31096, Israel

Phone numbers:

Mobile: +972-50-2061385

Home: +972-4-6562504

Work: +972-4-8542180

e-mail: m_suleiman@rambam.health.gov.il

2. ACADEMIC DEGREES

1993 B.Sc. degree in Medical Sciences (*cum laude*), the Bruce Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa.

1996 M.D. degree (*cum laude*), the Bruce Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa.

3. ACADEMIC APPOINTMENTS

03/2011 Senior Clinical Lecturer, Technion- Israel Institute of Technology, Haifa

05/2018 Associate C. Professor, Technion- Israel Institute of Technology, Haifa

4. PROFESSIONAL EXPERIENCE

8/2008- current	Attending physician, Cardiology, Cardiac Electrophysiology, Rambam Medical Center (Haifa)
2007-2008	Electrophysiology Fellowship, Cardiovascular Medicine Department, Mayo Clinic (Rochester, MN, USA)
2005-6/2007	Electrophysiology Fellowship, Rambam Medical Center (Haifa)
2000- 2003	Cardiology Fellowship, Cardiology Department, Rambam Medical Center (Haifa)
1997-2000	Internal Medicine Residency, Department of Medicine "D", Rambam Medical Center (Haifa)
1996-1997	Medical Internship, Hae'mik Medical center (Afula)

5. RESEARCH INTERESTS

- Statins for prevention of atrial fibrillation following pulmonary veins isolation
- Inflammation in acute coronary syndrome.
- Glucose metabolism in acute coronary syndrome
- Haptoglobin phenotype and cardiovascular diseases in diabetic patients
- Electroanatomic mapping of cardiac arrhythmias
- Sleep disorders and cardiac arrhythmias
- Outcomes of patients implanted with ICD/CRTD in different subgroups
- Peri-operative management of patients with cardiac implantable electronic devices.

6. TEACHING EXPERIENCE:

1997-current	4 th -6 th years medical students tutor, Medicine and Cardiology, Technion
2002-2005	Teaching in ACLS courses, Rambam Medical Center
2003-2007	Teaching in nurse's education courses, Technion
2009-current	2 nd year nursing school, Cardiology

2008-current	Introduction to Internal Medicine (American students program), Cardiology, Technion
2008-current	Advisor, ECG course for nurses at Rambam MC
2010-current	Cardiology Fellows (Technion and Jerusalem)

7. FACULTY ACTIVITIES

2010-2012	Member of the Israeli Cardiology Board Examination Committee
2010-current	Member of the national board committee for writing the final exam in Internal Medicine for medical students
2015-current	“More” exam, Technion
2015-current	Examiner, Final Internal Medicine Exam (Technion)

8. PUBLIC PROFESSIONAL ACTIVITIES

2008-current	Member of brain death determination committee, Rambam
2009-2013	Board Member of the Israel Working Group on Pacing and Electrophysiology
2010-current	Advisor and Instructor, the program of health science at Nazareth Baptists School
2015-current	Member of Mayo Clinic Fellowship committee
2014-current	Editorial Board member: Heart Rhythm Case reports Journal
2006-current	Reviewer for Scientific Journals: 1. Circulation 2. The American Journal of Cardiology 3. Journal of Internal Medicine 4. Heart Rhythm Journal 5. Heart Rhythm Case Reports 6. Heart 7. Journal of Interventional Cardiac Electrophysiology 8. Cardiovascular Diabetology
2017-current	Head of the Israeli Working Group on Pacing and Electrophysiology

9. MEMBERSHIP IN PROFESSIONAL SOCIETIES:

- Israel Heart Society
- European Society of Cardiology
- European Heart Rhythm Society
- Heart Rhythm Society

10. HONORS

1993	Diploma with honors (cum laude), Medical Sciences, Technion- Israel Institute of technology
1996	Medical Doctor (MD) with honors (cum laude), Technion- Israel Institute of Technology
2004	The H.N. Neufeld Award for excellent medical research.
2006	The H.N. Neufeld Award for excellent medical research.
2014	Excellence in Teaching Award, Technion- Israel Institute of Technology
2015	Excellence in Teaching Award, Technion- Israel Institute of Technology

11. GRADUATE STUDENTS

MD Theses

2004	Tarek Saa'di, MD, Inflammation and extent of coronary artery disease in patients undergoing coronary angiography. Primary supervisor: Mahmoud Suleiman.
2006	Rania El-Khatib, MD, Inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction. Primary Supervisor: Dr Doron Aronson. Additional supervisor: Dr Mahmoud Suleiman. (ref #8)
2007	Abeer Suleiman, Haptoglobin polymorphism and heart failure in patients with diabetes and acute myocardial infarction. Primary supervisor: Dr Andy Levy. Additional supervisor: Dr Mahmoud Suleiman.(ref #7)
2008	Rasha Zoabi, MD, Predictor value of admission glucose on epicardial and myocardial perfusion following primary percutaneous coronary intervention in

- patients with acute ST elevation myocardial infarction. Primary supervisor: Mahmoud Suleiman. Additional supervisor: Dr Monther Boulos
- 2009 Mohammed Hamad, MD, Correlation of culprit lesions complexity and TIMI risk score in patients with acute coronary syndrome. Primary supervisor: Mahmoud Suleiman. Additional supervisor: Dr Monther Boulos
- 2013 Narmeen Shehade, MD, Depression and Anxiety as Risk Factor for Ventricular Arrhythmias in ICD Recipients: Prospective Study. Primary supervisor: Mahmoud Suleiman.
- 2014 Tameem Zoabi, MD, Impact of surgical revisions on outcomes of patients with ICD or CRTD devices. Primary supervisor: Mahmoud Suleiman.
- 2015 Ido Goldenberg, MD, Prognostic Significance of Baseline Hemoglobin in Outcomes of Patients Implanted with ICD or CRTD. Primary supervisor: Mahmoud Suleiman

Basic Science

- 2014 Fedaa Ghanem, MD, Perioperative management of patients with cardiac implantable electronic devices: randomized controlled pilot trial (MAGNET trial), Primary supervisor: Mahmoud Suleiman

12. RESEARCH GRANTS

- 2007-2009 Atorvastatin for Prevention of Atrial Fibrillation Recurrence Following Pulmonary Veins Isolation: A Double-Blind, Placebo-Controlled, Randomized Trial. Pfizer, \$50,000, Paul Friedman (P.I., Mayo clinic, Rochester, US), Mahmoud Suleiman (Co P.I.).
- 2014 Perioperative MAnaGement of patieNts with cardiac implantable Electronic devices: randomized controlled clinical Trial (MAGNET trail). Israeli Working Group on Pacing and Electrophysiology, 70, 000 NIS (PI)
- 2012-2015 Implantable Cardioverter Defibrillator (ICD) in real world setting: data from the Israeli ICD registry. Boston Scientific, 200,000\$, Goldenberg Ilan (PI), Mahmoud Suleiman (Co P.I)

13. SIGNIFICANT PROFESSIONAL PROJECTS

- 2010 Design and implementation of National Registry of implantable defibrillators (ICDs) in Israel, an initiative of the Israeli Working Group on Pacing and Electrophysiology under the supervision of Prof Michael Glikson
- 2018 Design and execution of pacing course for technicians and nurses- Rambam College

14. PUBLICATIONS

Clinical Descriptive Research

1. **Suleiman M**, Gruberg L, Hammerman H, Aronson D, Halabi M, Goldberg A, Grenadier E, Boulus M, Markiewicz W, Beyar R. Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Eptifibatide and Abciximab: Outcomes, Complications and Thrombocytopenia During Percutaneous Coronary Intervention. *J Invasive Cardiol*. 2003; 15(6):319-323.
2. Nikolsky E, Gruberg L, Pechersky S, Kapeliovich M, Grenadier E, Amikam S, Boulos M, **Suleiman M**, Markiewicz W, Beyar R. Stent deployment failure: Reasons, implications, and short- and long-term outcomes. *Catheter Cardiovasc Interv*. 2003 ;59(3):324-8.
3. **Suleiman M**, Aronson D, Reisner S, Kapeliovich M, Markiewicz W, Levy Y, Hammerman H, Admission C-Reactive Protein is a Strong Independent Predictor of 30-Day Mortality in Patients with Acute Myocardial Infarction. *Am J Med*. 2003; 115(9):695-701
4. **Suleiman M**, Kapeliovich M, Roguin A, Aronson D, Meisel SR, Shochat M, Reisner S, Hammerman H, Lotan R, Levy NS, Levy AP. Haptoglobin type and 30-day mortality in diabetic individuals presenting with acute myocardial infarction. *Diabetes Care*. 2003; 26(9):2699-700

5. **Suleiman M**, Asleh R, Cabantchik ZI, Breuer W, Levy AP. Serum labile plasma iron is an independent and powerful predictor of mortality after myocardial infarction in individuals with diabetes mellitus. *Diabetes Care*. 2004; 27(11):2730-2732.
6. **Suleiman M**, Hammerman H, Boulos M, Kapeliovich MR, Suleiman A, Agmon Y, Markiewicz W, Aronson D. Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study. *Circulation*. 2005 ; 111(6):754-760.
7. **Suleiman M**, Aronson D, Kapeliovich MR, Roguin R, Meisel SR, Shochat M, Reisner SA, Markiewicz W, Hammerman H, Lotan R, Levy NS, Levy AP. Haptoglobin Polymorphism Predicts 30-Day Mortality and Heart Failure in Patients with Diabetes and Acute Myocardial Infarction. *Diabetes*. 2005; 54(9):2802-2806.
8. **Suleiman M**, Khatib R, Mahamid R, Boulos M, Kapeliovich M.R, Levy Y, Hammerman H, Markiewicz W, Aronson D. Early Inflammation and Risk of Long-Term Development of Heart Failure and Mortality in Survivors of Acute Myocardial Infarction: Predictive Role of C-Reactive Protein. *J Am Coll Cardiol*. 2006; 47:962-968
9. Gruberg L, **Suleiman M**, Kapeliovich M, Hammerman H, Grenadier E, Boulos M, Amikam S, Markiewicz W, Beyar R. Glycoprotein IIb/IIIa Inhibitors during Rescue Percutaneous Coronary Intervention in Acute Myocardial Infarction. *J Invasive Cardiol*. 2006; 18:59–62
10. Goldsher D, Amikam S, Boulos M, **Suleiman M**, Shreiber R, Eran A, Goldshmid Y, Mazbar R, Roguin A. Magnetic Resonance Imaging for Patients with Permanent Pacemakers: Initial Clinical Experience. *Isr Med Assoc J*. 2006; 8:91–94.
11. Dragu R, Huri S, Zuckerman R, **Suleiman M**, Mutlak D, Agmon Y, Kapeliovich MR, Beyar R, Markiewicz W, Hammerman H, Aronson D. Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction. *Atherosclerosis*. 2008; 196(1):405-412
12. **Suleiman M**, Gepstein L, Roguin A, Beyar R, Boulos M. Catheter ablation of cardiac arrhythmias guided by electroanatomic imaging (CARTO): a single-center experience. *Isr Med Assoc J*. 2007; 9(4):260-264.
13. Aronson D, Hammerman H, Kapeliovich MR, Suleiman A, Agmon Y, Beyar R, Markiewicz W, **Suleiman M**. Fasting glucose in acute myocardial infarction: incremental

- value for long-term mortality and relationship with left ventricular systolic function. *Diabetes Care*. 2007; 30(4):960-966
14. Aronson D, **Suleiman M**, Agmon Y, Suleiman A, Blich M, Kapeliovich MR, Beyar R, Markiewicz W, Hammerman H. Changes in haemoglobin levels during hospital course and long-term outcome after acute myocardial infarction. *Eur Heart J*. 2007; 28(11):1289-1296.
 15. Glikson M, **Suleiman M**, Luria DM, Martin ML, Hodge DO, Shen WK, Bradley DJ, Munger TM, Rea RF, Hayes DL, Hammill SC, Friedman PA. Do Abandoned Leads Pose Risk to ICD Patients? *Heart Rhythm*. 2009; 6(1):65-68.
 16. Aronson D, Hammerman H, **Suleiman M**, Markiewicz W. Usefulness of changes in fasting glucose during hospitalization to predict long-term mortality in patients with acute myocardial infarction. *Am J Cardiol*. 2009; 104(8):1013-7
 17. AbouEzzeddine O, **Suleiman M**, Buescher T, Friedman PA, Jahangir A, Mears JA, Ladwing DJ, Munger TM, Hammill SC, Packer DL, Asirvatham SJ. Relevance of endocavitary structures in ablation procedures for ventricular tachycardia. *J Cardiovasc Electrophysiol*. 2010; 21(3):245-254
 18. Blich M, **Suleiman M**, Zeidan Shwiri T, Marai I, Boulos M, Amikam S. Long term outcome of VDD mode pacing in patients with atrioventricular block using a single lead. *Clin Cardiol*. 2010; 33(1):18-22
 19. Marai I, **Suleiman M**, Blich M, Zeidan-Shwiri T, Gepstien L, Boulos M. Clinical and Electrophysiologic Outcomes of Patients Undergoing Percutaneous Endocardial Ablation of Scar – Related Ventricular Tachycardia: Single Center Experience. *Isr Med Assoc J*. 2010;12(11):667-70
 20. Zeidan-Shwiri T, Aronson D, Atalla K, Blich M, **Suleiman M**, Marai I, Gepstein L, Lavie L, Lavie P, Boulos M. Circadian pattern of life-threatening ventricular arrhythmia in patients with sleep-disordered breathing and implantable cardioverter-defibrillators. *Heart Rhythm*. 2011;8(5):657-62.
 21. **Suleiman M**, Brady PA, Asirvatham SJ, Friedman PM, Munger TM. The Non-Coronary Cusp as a Site for Successful Ablation of Accessory Pathways – Electrogram Characteristics in Three Cases. *J Cardiovas Electrophysiology*. *J Cardiovasc Electrophysiol*. 2011;22(2):203-9

22. Eliyahu S, Roguin A, Kerner A, Boulos M, Lorber A, Halabi M, **Suleiman M**, Nikolsky E, Rispler S, Beyar R. Patient safety and outcomes from live case demonstrations of interventional cardiology procedures. *JACC Cardiovasc Interv.* 2012;5(2):215-24
23. Marai I, Khoury A, **Suleiman M**, Gepstein L, Blich M, Lorber A, Boulos M. Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia. *Am J Cardiol.* 2012;110(1):72-6.
24. Khoury A, Marai I, **Suleiman M**, Blich M, Lorber A, Gepstein L, Boulos M. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm.* 2013;10(11):1671-5.
25. **Suleiman M**, Goldenberg I, Haim M, Schliamser JE, Boulos M, Ilan M, Swissa M, Gavrielov-Yusim N, Fuchs T, Amit G, Glikson M; Israeli Working Group on Pacing and Electrophysiology. Clinical characteristics and outcomes of elderly patients treated with an implantable cardioverter-defibrillator or cardiac resynchronization therapy in a real-world setting: data from the Israeli ICD Registry. *Heart Rhythm.* 2014;11(3):435-41
26. Arnson Y*, **Suleiman M***, Glikson M, Sela R, Geist M, Amit G, Schliamser JE, Goldenberg I, Ben-Zvi S, Orvin K, Rosenheck S, Adam Freedberg N, Strasberg B, Haim M. Role of defibrillation threshold testing during implantable cardioverter-defibrillator placement: data from the Israeli ICD Registry. *Heart Rhythm.* 2014;11(5):814-21. (***equal contribution**)
27. Amit G, **Suleiman M**, Konstantino Y, Luria D, Kazatsker M, Chetboun I, Haim M, Gavrielov-Yusim N, Goldenberg I, Glikson M; On behalf of the Israeli Working Group on Pacing and Electrophysiology. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry. *Europace.* 2014;16(8):1175-80
28. Eisen A*, **Suleiman M***, Strasberg B, Sela R, Rosenheck S, Freedberg NA, Geist M, Ben-Zvi S, Goldenberg I, Glikson M, Haim M. Renal Dysfunction and Clinical Outcomes of Patients Undergoing ICD and CRTD Implantation: Data from the Israeli ICD Registry. *J Cardiovasc Electrophysiol.* 2014; 25(9):990-7. (***equal contribution**)

29. **Suleiman M**, Goldenberg I, Samniah N, Rosso R, Marai I, Pekar A, Steiner H, Khalameizer V, Militianu A, Glikson M. Outcome of Patients with Advanced Heart Failure who Receive Device-Based Therapy for Primary Prevention of Sudden Cardiac Death: Insights from the Israeli ICD Registry . *Pacing Clin Electrophysiol*. 2015; 38(6):738-45
30. Sabbag A, **Suleiman M**, Glick A, Fuchs T, Medina A, Golovchiner G, Steiner H, Goldenberg I, Glikson M, Beinart R. Ethnic differences among implantable cardioverter defibrillators recipients in Israel. *Am J Cardiol*. 2015 ;115(8):1102-6
31. Blich M, Marai I, **Suleiman M**, Lorber A, Gepstein L, Boulous M, Khoury A. Electrocardiographic comparison of ventricular premature complexes during exercise test in patients with CPVT and healthy subjects. *Pacing Clin Electrophysiol*. 2015;38(3):398-402
32. Sabbag A, **Suleiman M**, Laish-Farkash A, Samania N, Kazatsker M, Goldenberg I, Glikson M, Beinart R; Israeli Working Group of Pacing and Electrophysiology. Contemporary rates of appropriate shock therapy in patients who receive implantable device therapy in a real-world setting: From the Israeli ICD Registry. *Heart Rhythm*. 2015;12(12):2426-33
33. Blich M, Efrati E, Marai I, **Suleiman M**, Gepstein L, Boulous M. Novel Clinical Manifestation of the Known SCN5A D1790G Mutation. *Cardiology*. 2015;132(4):228-32.
34. Soucek F, Covassin N, Singh P, Ruzek L, Kara T, **Suleiman M**, Lerman A, Koestler C, Friedman PA, Lopez-Jimenez F, Somers VK. Effects of Atorvastatin (80 mg) Therapy on Quantity of Epicardial Adipose Tissue in Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation. *Am J Cardiol*. 2015;116(9):1443-6.
35. Laish-Farkash A, **Suleiman M**. Primary Versus Secondary Atrial Fibrillation: Is it Time for a Different Classification of Atrial Fibrillation? *J Cardiovasc Electrophysiol*. 2015 Sep 22. doi: 10.1111/jce.12840.
36. Bogdan S, Nof E, Eisen A, Sela R, Rosenheck S, Freedberg N, Geist M, Ben-Zvi S, Haim M, Glikson M, Goldenberg I, **Suleiman M**; Israeli working group of pacing and electrophysiology of the Israeli Heart Society. Clinical Outcomes in Patients with Severe Renal Dysfunction Including Dialysis Following Defibrillator Implantation. *Am J Nephrol*. 2015;42(4):295-304

37. Marai I, Boulos M, Lessick J, Abadi S, Blich M, **Suleiman M**. Outflow tract ventricular arrhythmia originating from the aortic cusps: our approach for challenging ablation. *J Interv Card Electrophysiol*. 2015 Nov 16. [Epub ahead of print]
38. Konstantino Y, Haim M, Boxer J, Goldenberg I, Feldman, Michowitz Y, Glikson M, **Suleiman M**. Clinical Outcomes of Single vs. Dual Chamber Implantable Cardioverter Defibrillators: Lessons from the Israeli ICD Registry. *J Cardiovasc Electrophysiol*. 2016 Feb 8. doi: 10.1111/jce.
39. Marai I, **Suleiman M**, Blich M, Lessick J, Abadi S, Boulos M. Impact of computed tomography image and contact force technology on catheter ablation for atrial fibrillation. *World J Cardiol*. 2016;8(4):317-22.
40. Matsuzawa Y, **Suleiman M**, Guddeti RR, Kwon TG, Monahan KH, Lerman LO, Friedman PA, Lerman A. Age-Dependent Predictive Value of Endothelial Dysfunction for Arrhythmia Recurrence Following Pulmonary Vein Isolation. *J Am Heart Assoc*. 2016 Sep 9;5(9).
41. Laish-Farkash A, Bruoha S, Katz A, Goldenberg I, **Suleiman M**, Michowitz Y, Shlomo N, Einhorn-Cohen M, Khalameizer V. Morbidity and mortality with cardiac resynchronization therapy with pacing vs. with defibrillation in octogenarian patients in a real-world setting. *Europace*. 2016 Oct 12. pii: euw238.
42. Leshem E, **Suleiman M**, Laish-Farkash A, Haim M, Geist M, Luria D, Glikson M, Goldenberg I, Michowitz Y; Israeli Working Group of Pacing and Electrophysiology. Impact of quadripolar LV leads on heart failure hospitalization rates among patients implanted with CRT-D: data from the Israeli ICD Registry. *J Interv Card Electrophysiol*. 2018 Jan;51(1):5-12.
43. Laish-Farkash A, Suleiman M. Comparison of the Efficacy of PVAC® and nMARQ™ for paroxysmal atrial fibrillation. *J Atr Fibrillation*. 2017 Apr 30;9(6):1550
44. Goldenberg I, Barsheshet A, Laish-Farkash A, Swissa M, Schliamser JE, Michowitz Y, Glikson M, **Suleiman M**; Israeli Working Group on Pacing and Electrophysiology. Anemia and the Risk of Life-threatening Ventricular Tachyarrhythmias from the Israeli Implantable Cardioverter Defibrillator Registry. *Am J Cardiol*. 2017 Dec 15;120(12):2187-2192.

45. Dabbah S, Chertin L, Khateeb A, Rosenfeld I, **Suleiman M**, Halabi M. Red cell distribution width predicts death and appropriate therapy in patients with implantable cardioverter defibrillator: A simple measurement with prognostic value in a variety of diseases, may help in better selection of patients who will benefit the most from this device. *Pacing Clin Electrophysiol.* 2017 Dec;40(12):1384-1388.
46. Laish-Farkash A, **Suleiman M**. Evaluation of left atrial thrombus prior to catheter ablation of atrial fibrillation: Is it time for an individualized approach? *J Cardiovasc Electrophysiol.* 2017 Oct;28(10):1137-1139.
47. Steiner H, Geist M, Goldenberg I, Suleiman M, Glikson M, Tenenbaum A, Swissa M, Fisman EZ, Golovchiner G, Strasberg B, Barsheshet A; Israeli Working Group of Pacing and EP. Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry. *Cardiovasc Diabetol.* 2016 Dec 1;15(1):160

Review papers (all are invited)

1. **Suleiman M**, Asirvatham SJ. Ablation above the Semilunar Valves: When, Why, and How?. Part I. *Heart Rhythm*. 2008; 5(10):1485-1492.
2. **Suleiman M**, Asirvatham SJ. Ablation above the Semilunar Valves: When, Why, and How?. Part II. *Heart Rhythm*. 2008; 5(11):1625-1630
3. **Suleiman M**, Aronson D. Impact of Atrial Fibrillation on cardiovascular mortality in the setting of myocardial infarction. *Journal of atrial fibrillation*. 2013;5(4):39-48

Case Reports

1. **Suleiman M**, Volfovitz E, Boulman N, Levy Y. Adult onset Still's disease as a cause of ARDS and acute respiratory failur. *Scand J Rheumatol* 2002; 31:181-183.
2. **Suleiman M**, Munger TM, Powel DB, Asirvatham SJ. Successful cryoablation in the noncoronary aortic cusp for a left anteroseptal accessory pathway. *J Interv Card Electrophysiol*. 2008; 23(3):205-211
3. Habib A , Friedman PA, Cooper LT, **Suleiman M**, Asirvatham AJ. Cardiac calcified amorphous tumor in a patient presenting for ventricular tachycardia ablation: intracardiac echocardiogram diagnosis and management. *J Interv Card Electrophysiol*. 2009; 21:
4. Marai I, **Suleiman M**, Lorber A, Boulos M. Iatrogenic intra-atrial macro-reentrant tachycardia following transcatheter closure of atrial septal defect treated by radiofrequency ablation. *Ann Pediatr Cardiol*. 2011;4(2):192-4
5. Marai I, Koskosi M, Keidar Z , **Suleiman M** and Samia Massalha. QTc Prolongation after a Negative Dipyridamole Pharmacological Stress Study. *Cardiol Pharmacol*. 2013; 3: 114
6. Marai I, Gepstein L, Boulos M, **Suleiman M**. Ablation of Idiopathic Ventricular Fibrillation Triggered by Ventricular Premature Beat Originating from Myocardium of Right Ventricle: Case report. *Journal of Cardiology Cases*. 2014; 9 (3):109-112

15. CONFERENCES

Invited Talks

National

1. PCI in the Elderly. The 2nd Elderly Medicine Meeting, Tel-Aviv, Israel, 2004
2. Abandoned Leads and Risk to ICD Patients. Israeli Working Group on Electrophysiology and Pacing Annual Meeting. Kfar Bloom, 2009
3. Ablation above the semilunar valves: When, why, and how? Israeli Working Group on Electrophysiology and Pacing Annual Meeting. Kfar Bloom, Feb 2009
4. Dronedarone for rate control in AF. ? Israeli Working Group on Electrophysiology and Pacing Annual Meeting. Tel Aviv, April 2009
5. Invasive management of cardiac arrhythmias. The 2nd Arab Society Health conference. Nazareth, May 2010
6. Cardiac Resynchronization therapy in 2011. Israeli Working Group on Electrophysiology and Pacing Annual Meeting. Jerusalem, Israel, Dec 2010
7. Invasive management of atrial fibrillation. Nazareth Hospital Staff Meeting. Jan 2012
8. Ventricular Arrhythmias. The 3rd Arab Society Health conference. Nazareth, May 2012
9. Ventricular arrhythmias in setting of acute coronary syndrome. Joint meeting of the Israeli Working Groups on Electrophysiology and Pacing and Intensive Coronary Care. Tel Aviv, Jan 2016
10. Chairperson- Cardio Femme meeting. Kfar Blome, Jul 2017
11. Chairperson- The annual congress of the Israeli Heart Society. Tel Aviv, April 2017
12. Chairperson- The annual congress of the Israeli Heart Society. Tel Aviv, April 2017
13. How to Optimize Atrial Fibrillation Diagnosis and Management. The annual congress of the Israeli Heart Society- Plenary Session-Joint meeting with the American Heart Association. Tel Aviv, April 2018

International

1. Press conference at the American College of Cardiology (ACC) annual meeting, New Orleans, USA, 2004

2. Press conference at the American College of Cardiology (ACC) annual meeting, Atlanta, USA, 2006
3. Atrial Fibrillation in Athletes. The 10th International Dead Sea Symposium on Arrhythmias, Te-Aviv, Israel, 2010.
4. Update in Atrial Fibrillation Ablation, Romanian Society of Cardiology Annual meeting, Bucharest, Romania, 2010
5. Report from the National Israeli ICD Registry. Heart Rhythm Scientific Meeting, San Francisco, USA, 2011
6. Cardiac Resynchronization Therapy. Ukraine Society of Cardiology annual meeting, Kiev, Ukraine, April 2012
7. Overview of the Israeli National ICD Registry and Comparison to North American and Other International Registries. Heart Rhythm Scientific Meeting, Denver, USA, May 2013
8. Overview of the Israeli National ICD Registry. The 11th International Dead Sea Symposium on Arrhythmias, Te-Aviv, Israel, 2012.
9. Updates on Cardiac Resynchronization Therapy- Russian Society of Cardiology annual meeting, Moscow, Russia, June 2013
10. Lessons from the Israeli ICD Registry. The 12th International Dead Sea Symposium on Arrhythmias, Te-Aviv, Israel, 2014.
11. Trends in ICD Implantation Indications and Outcomes. European Heart Rhythm Association Annual Meeting, Milan, Italy, 2015
12. Israeli ICD Registry- Overview of Organization, Methodology and Initial Results. World Congress on Cardiac Arrhythmias, Beijing, China, 2015
13. Cardiac Rhythm Devices of Today and Tomorrow, Innovations in Cardiovascular Interventions (ICI), Tel-Aviv, Israel, 2015
14. The Israeli ICD Registry: Current Practice and Results of Treatment with ICDs. American College of Cardiology (ACC) annual meeting, Chicago, USA, April 2016
15. Predicting ICD therapy in real World. European Heart Rhythm Association Annual Meeting, Vienna, Austria, 2017
16. Chairperson- Innovations in Cardiovascular Interventions (ICI) meeting, Tel-Aviv, Israel, Dec 2017

Participation in organizing conferences

2012-current Member of the organizing committee of the International Dead Sea Symposium (IDSS), Tel-Aviv

Contributed Talks and Abstracts

1. **Suleiman M**, Gruberg L, Hammerman H, Aronson D, Halabi M , Goldberg A, Nikolsky E, Grenadier E, Boulus M, Markiewicz W, Beyar R. Comparison of two platelet glycoprotein IIb/IIIa Inhibitors, Eptifibatide and Abciximab, in the in-hospital outcomes and thrombocytopenia during percutaneous coronary intervention. *Israeli Heart Society Meeting*, Tel-Aviv, IL, 2002. Oral presentation
2. **Halabi M**, Nekolsky E, Ben-Zvi M, Hoffman A, **Suleiman M**, Gruberg L, Kouperberg E, Markiewicz W, Beyar R. Carotid stenting in high risk patients- a single center experience. *Israeli Heart Society Meeting*, Tel-Aviv, IL, 2002. Oral presentation
3. **Suleiman M**, Rogiun A, Nikolsky A, Halabi M, Beyar R, Markiewicz W. Impact of normal or non-significant coronary angiographic findings on discharge diagnosis and medical recommendations. *Israeli Heart Society Meeting*, Tel-Aviv, IL, 2002. Poster presentation
4. **Nikolsky E**, Kapeliovich M, Pechersky S, Grenadier E, Amikam S, Boulus M, Gruberg L, **Suleiman M**, Futerman B, Markiewicz W, Beyar R. Failed coronary stent deployment: single center experience. *Israeli Heart Society Meeting*, Tel-Aviv, IL, 2002. Oral presentation
5. **Suleiman M**, Aronson D, Pecherski S, Rogiun A, Shwiri-Zidan T, Markiewicz W. Influence of external or internal cardioversion on cardiac troponin T and other conventional cardiac markers. *Israeli Heart Society Meeting*, Tel-Aviv, IL, 2002. Oral presentation
6. **Suleiman M**, Levy Y, Aronson D, Roguin A, Halabi M, Kapeliovich M, Hamermman H. Is C-reactive protein level a useful marker of severity and infarct size in patients with

- acute ST elevation myocardial infarction? *European Society of Cardiology*, Berlin, Germany, 2002. Poster presentation
7. **Suleima M**, Gruberg L, Halabi M, Nikolsky E, Grenadier E, Boulus M, Markiewicz W, Beyar R. Comparison eptifibatide and abciximab in the in-hospital outcomes and thrombocytopenia during percutaneous coronary intervention. *European Society of Cardiology*, Berlin, Germany, 2002. Poster presentation
 8. **Halabi M**, Nekolsky E, Hoffman A, Rogiun A, **Suleiman M**, Gruberg L, Kouperberg E, Markiewicz W, Beyar R. Carotid stenting in high risk patients- a single center experience. *European Society of Cardiology*, Berlin, Germany, 2002. Poster presentation
 9. **Suleiman M**, Gruberg L, Hammerman H, Aronson D, Kpeliovich M, Grenadier E, Boulus m, Halabi M, Amikam S, Markiewicz W, Beyar R. The correlation between C-reactive protein and the extent of coronary artery disease in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. *Israeli Heart Society Meeting*, Tel-Aviv, IL, 2003. Oral presentation
 10. **Suleiman M**, Gruberg L, Hammerman H, Aronson D, Roguin A, Kapeliovich M, Grenadier E, Boulus M, Markiewicz W, Beyar R. Complex coronary culprit lesions are associated with higher TIMI Risk Score in patients with Non-ST elevation acute coronary syndromes. *Israeli Heart Society Meeting*, Tel-Aviv, IL, 2003. Oral presentation
 11. **Suleiman M**, Kapeliovich M, Roguin A, Aronson D, Reisner SA, Hammerman H, Lotan R, Levy NS, Levy AP. A Common allelic polymorphism which predicts infarct size and 30-day adverse cardiac events in patients with acute myocardial infarction. *Israeli Heart Society Meeting*, Tel-Aviv, IL, 2003. Oral presentation
 12. **Gruberg L**, **Suleiman M**, Kapeliovich M, Hammerman H, Grenadier E, Boulus M, Markiewicz W, Beyar R. Glycoprotein IIb/IIIa inhibitors after full-dose thrombolysis in rescue angioplasty for acute myocardial infarction: To give or not give? *Transcatheter Cardiovascular Therapeutics (TCT)*, Washington, US, 2003. Poster presentation
 13. **Suleiman M**, Gruberg L, Kerner A, Aronson D, Boulus M, Markiewicz W, Beyar R. Elevated levels of admission C-reactive protein are not a marker of extensive coronary artery disease in patients undergoing primary percutaneous coronary intervention in acute

- myocardial infarction. *Transcatheter Cardiovascular Therapeutics (TCT)*, Washington, US, 2003. Poster presentation.
14. **Suleiman M**, Kapeliovich MR, Roguin A, Aronson D, Meisel SR, Reisner SA, Hammerman H, Lotan R, Levy NS, Levy AP. Haptoglobin phenotype and 30-Day mortality in diabetic individuals presenting with acute myocardial infarction. *American Heart Association Annual Meeting*, Chicago, US, 2003. Oral Presentaion
 15. **Suleiman M**, Markiewicz W, Kapeliovich M, Hammerman H, Aronson D. Prognostic significance of stress hyperglycemia in nondiabetic patients with acute myocardial infarction: a prospective study. *European Society of Cardiology* , Vienna, Austria, 2003. Poster presentation
 16. **Suleiman M**, Aronson D, Kapeliovich M, Kerner a, Levy y, Hammerman H. C-reactive protein levels as an early predictor of 30-day mortality in patients with acute myocardial infarction. *American College of Cardiology (ACC) annual meeting*, New Orleans, USA, 2004. Oral presentation
 17. Gruberg L, **Suleiman M**, Kapellovich M, Hammerman H, Grenadier E, Boulus M, Markiewicz W, Beyar R. Glycoprotein IIb/IIIa inhibitors after full dose thrombolysis in rescue angioplasty for acute myocardial infarction: *American College of Cardiology (ACC) annual meeting*, New Orleans, USA, 2004. Poster presentation
 18. **Suleiman M**, Markiewicz W, Khatib R, Mahamid R, Kapeliovich MR, Levy Y, Hammerman H, Aronson D. C-Reactive protein on admission is an independent predictor of 1-year mortality in patients with acute myocardial infarction: A prospective study. *American College of Cardiology (ACC) annual meeting*, New Orleans, US, 2004. Poster presentation
 19. **Suleiman M**, Markiewicz W, Kapeliovich M, Hammerman H, Aronson D. Prognostic significance of stress hyperglycemia in nondiabetic patients with acute myocardial infarction: A prospective study. *American College of Cardiology (ACC) annual meeting*, New Orleans, US, 2004. Oral presentation
 20. **Suleiman M**, Aronson D, Kapeliovich MR, Markiewicz W, Hammerman H, Suleiman A, Levy NS, Levy Ap. Haptoglobin polymorphism is associated with short-term mortality

- and heart failure in patients with diabetes and acute myocardial infarction. *European Society of Cardiology*, Munich, Germany, 2004. Poster presentation.
21. Roguin A, Zviman M, Goldsher D, Amikam S, Boulos M, **Suleiman M**, Nazarian S, Halperin HR. Can patients with pacemakers and implantable cardioverter-defibrillator systems undergo MRI safely? In-vitro, in-vivo and initial clinical experience. *European Society of Cardiology*, Stockholm, Sweden, 2005. Oral presentation.
22. Gruberg L, **Suleiman M**, Pechersky S, Nikolsky E, Grenadier E, Boulos M, Markiewicz W, Beyar R. Five years after intracoronary radiation for the prevention of in-stent restenosis: not as hot as we thought. *European Society of Cardiology*, Stockholm, Sweden, 2005. Poster presentation.
23. **Suleiman M**, Hammerman H, Kapeliovich M, Agmon Y, Boulos M, Beyar R, Markiewicz W, Aronson D. Fasting glucose is a powerful independent risk factor for long-term mortality in patients with acute myocardial infarction. A prospective study. *European Society of Cardiology*, Stockholm, Sweden, 2005. Poster presentation.
24. Dragu R, Aronson D, Zukerman R, **Suleiman M**, Rispler S, Markiewicz W, Kapeliovich M, Hammerman H. Lymphopenia in the early phase of ST-elevation myocardial infarction is a prognostic marker of long-term mortality. *European Society of Cardiology*, Stockholm, Sweden, 2005. Poster presentation.
25. **Suleiman M**, Hammerman H, Kapeliovich M, Agmon Y, Boulos M, Beyar R, Markiewicz W, Aronson D. Fasting glucose is a powerful independent risk factor for long-term mortality in patients with acute myocardial infarction. A prospective study. *American College of Cardiology (ACC) annual meeting*, Atlanta, US, 2006. Oral presentation
26. Aronson D, **Suleiman M**, Agmon Y, Blich M, Kapeliovich MR, Beyar R, Markiewicz W, Hammerman H. Effect of nadir hemoglobin during hospital course on the long-term risk of heart failure and death in survivors of acute myocardial infarction. *American College of Cardiology (ACC) annual meeting*, Atlanta, US, 2006. Oral presentation
27. **Suleiman M**, Boulos M, Hammerman H, Suleiman A, Kapeliovich MR, Markiewicz W, Aronson D. Elevated levels of C-reactive protein are associated with new onset atrial

- fibrillation in patients with acute myocardial infarction. *Heart Rhythm Society*, Boston, US, 2006. Poster presentation.
28. AbouEzzedine O, **Suleiman M**, Friedman PA, Mears J, Buescher T, Packer DL, Asirvatham SJ. Relevance of endocavitary structures during ablation for ventricular tachycardia. The international Dead Sea symposium on cardiac arrhythmias and device therapy, Tel-Aviv, IL, 2008. Poster presentation.
29. Boulos M, **Suleiman M**, La-meir M, De Roy L, Cohen O, Bolotin G. The one Step electrophysiological and surgical approach for treatment of atrial fibrillation. *Israrli Heart Society* annual meeting, Tel-Aviv, IL, 2010. Oral presentation
30. **Suleiman M**, Koestler C, Lerman A, Jimenez L, Herges R, Hodge D, Bradely D, Cha YM, Brady PA, Munger TM, Shen WK, Asirvatham SJ, Packer DL, and Friedman PA. Atorvastatin for Prevention of Atrial Fibrillation Recurrence Following Pulmonary Veins Isolation: A Double-Blind, Placebo-Controlled, Randomized Trial. Heart Rhythm Scientific Meeting, San Francisco, USA, 2011. Oral presentation.
31. Zeidan Shwiri T, Aronson D, Atalla K, **Suleiman M**, Marai I, Gepstien L, Blich M, Boulos M, Lavie L, Lavie P. Circadian Pattern of Life-Threatening Ventricular Arrhythmia in Patients with Sleep-Disordered Breathing and Implantable Cardioverter-Defibrillators. Heart Rhythm Scientific Meeting, San Francisco, USA, 2011. Poster presentation.
32. **Suleiman M**, Haim M, Schliamser JE, Boulos M, Viskin S, Swissa M, Gavrielov-Yusim N, Fuchs T, Goldenberg I, and Glikson M. Clinical Characteristics and Outcomes of Elderly Patients Treated With ICD and CRTD in Real World Setting: Data From the Israeli ICD Registry. Heart Rhythm Scientific Meeting, Denver, USA, 2013. Moderated poster.
33. **Suleiman M**, Goldenberg I, Samniah N, Rosso R, Marai I, Pekar A, Steiner H, Khalameizer V, Militianu A, and Glikson M. Outcome of patients with advanced heart failure who receive device-based therapy for primary prevention of sudden cardiac death: insights from the israeli ICD registry. European Heart Rhythm Society Scientific Meeting, Athens, Greece, 2013. Oral presentation

